• TickerNVCR
  • ISINJE00BYSS4X48
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryJersey
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Novocure Ltd: 2 directors

Two Directors at Novocure Ltd sold/sold after exercising options 24,810 shares at between 210.010USD and 215.000USD. The significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is ...

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Novocure Ltd: 2 directors

Two Directors at Novocure Ltd sold/sold after exercising options 24,810 shares at between 210.010USD and 215.000USD. The significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is ...

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 01 2021 6:51AM

NOVOCURE sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of NOVOCURE (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date March 2, 2021, the closing price was USD 153.09 and its target price was estimated at USD 120.90.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch